in order to study the periplasmic expression of human growth hormone (hgh) in escherichia coli, the related cdna was inserted in two expression plasmids carrying pelb signal peptide, one with lac bacterial promoter and the other with a bacteriophage t7-based promoter. the recombinant plasmids were moved to tg1 and bl21 strains of e. coli, respectively. to induce the expression systems, iptg and...

BACKGROUND Human growth hormone (hGH) is a single-chain polypeptide that participates in a wide range of biological functions such as metabolism of proteins, carbohydrates and lipids as well as in growth, development and immunity. Growth hormone deficiency in human occurs both in children and adults. The routine treatment for this condition is administration of recombinant human growth hormone ...

the first successful treatment of growth hormone (gh) deficient children with gh extracted from human pituitary was introduced during late 1950's.  the subsequent availability and use of recombinant gh (rhgh) for different clinical conditions raised the question of whether this new therapeutic modality increases the risk of certain conditions such as leukemia or malignancy.  herein, we report o...

Oral absorption and room temperature storage remain two major challenges limiting the bioavailability of recombinant human growth hormone (rhGH) due to need overcome unfavorable gastrointestinal environment resist effects on rhGH structure, Therefore, we designed a multifunctional nanoplatform address both problems simultaneously. The carrier consists PLGA, ionic liquid (IL) deoxycholic acid (D...

The first successful treatment of growth hormone (GH) deficient children with GH extracted from human pituitary was introduced during late 1950's.  The subsequent availability and use of recombinant GH (rhGH) for different clinical conditions raised the question of whether this new therapeutic modality increases the risk of certain conditions such as leukemia or malignancy.  Herein, we report o...

the delivery of therapeutic proteins has gained momentum with development of biotechnology. however, large molecular weight, hydrophilic nature and susceptibility to harsh environment of gastrointestinal tract (git) resulted in low absorption. the main objective of this work was the design of a particulate system for oral delivery of recombinant human growth hormone (rhgh) on the basis of parti...

The delivery of therapeutic proteins has gained momentum with development of biotechnology. However, large molecular weight, hydrophilic nature and susceptibility to harsh environment of gastrointestinal tract (GIT) resulted in low absorption. The main objective of this work was the design of a particulate system for oral delivery of recombinant human growth hormone (rhGH) on the basis of parti...

The delivery of therapeutic proteins has gained momentum with development of biotechnology. However, large molecular weight, hydrophilic nature and susceptibility to harsh environment of gastrointestinal tract (GIT) resulted in low absorption. The main objective of this work was the design of a particulate system for oral delivery of recombinant human growth hormone (rhGH) on the basis of parti...

Background/Aims: Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) both contribute to growth. To determine if recombinant human (rh)GH + rhIGF-1 therapy is more effective than rhGH alone to treat short stature, we assessed the efficacy and safety of coadministered rhGH + rhIGF-1 in short children with GH sufficiency and low IGF-1. Methods: In a 3-year, randomized, multicenter, open-l...

Growth hormone (GH) stimulation tests are considered a prerequisite to clinical trials of recombinant human GH (rhGH) therapy, but the test results may not be predictive of the treatment outcomes with rhGH. We examined the GH stimulation test results as a predictor of the treatment outcome in a cohort of prepubertal subjects in the National Cooperative Growth Study. A standard is proposed in wh...